Abalos’ arena: planning to upstage oncolytic viruses
Abalos launches with €12 million series A to advance its arenavirus-based cancer therapies
Abalos launched Tuesday with a €12 million ($13.2 million) series A round to advance its arenavirus-based cancer therapies, which offer an alternative to oncolytic viruses, and rely on prolonged immune responses to clear tumors.
Boehringer Ingelheim Venture Fund and Gründerfonds Ruhr co-led the tranched round with participation from NRW.BANK and High-Tech Gründerfonds.
A spin-off from the University of Duisburg-Essen and the University of
